|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Cytomyx Therapeutics, Inc.
| | | Phone: | (650) 515-3185 | Fax: | (650) 351-0353 | Year Established: | 2008 | Ticker: | CTMX | Exchange: | NASDAQ | Main Contact: | Sean McCarthy, D. Phil., President & CEO | | Other Contacts: | Lloyd A. Rowland, Jr., Senior VP & General Counsel Sridhar Viswanathan, Ph.D., VP, Process Sciences and Manufacturing Operations Alison Joly, Ph.D., VP, Program and Alliance Management Rachel Humphrey, M.D., CMO Debanjan Ray, CFO & Head, Corporate Development and Strategy W. Michael Kavanaugh, M.D., CSO
| | Company Description | CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and develop first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. | |
|
|
|
|
|